PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.09% | 24.71% | 20.31% | -25.04% | -33.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.04% | 21.16% | 19.59% | -21.89% | -30.74% |
| Operating Income | -38.04% | -21.16% | -19.59% | 21.89% | 30.74% |
| Income Before Tax | -1,334.66% | -163.36% | -116.20% | -131.19% | -104.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,334.66% | -163.36% | -116.20% | -131.19% | -104.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,334.66% | -163.36% | -116.20% | -131.19% | -104.18% |
| EBIT | -38.04% | -21.16% | -19.59% | 21.89% | 30.74% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -708.68% | -199.27% | -185.70% | -230.46% | -130.66% |
| Normalized Basic EPS | -1,509.12% | -297.56% | -427.71% | -481.67% | -107.13% |
| EPS Diluted | -708.68% | -199.27% | -185.70% | -230.46% | -130.66% |
| Normalized Diluted EPS | -1,509.12% | -297.56% | -427.71% | -481.67% | -107.13% |
| Average Basic Shares Outstanding | 32.59% | 14.31% | -3.58% | -15.57% | -15.90% |
| Average Diluted Shares Outstanding | 32.59% | 14.31% | -3.58% | -15.57% | -15.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |